Zoledronic acid causes enhancement of bone growth into porous implants.
The effect of zoledronic acid on bone ingrowth was examined in an animal model in which porous tantalum implants were placed bilaterally within the ulnae of seven dogs. Zoledronic acid in saline was administered via a single post-operative intravenous injection at a dose of 0.1 mg/kg. The ulnae were harvested six weeks after surgery. Undecalcified transverse histological sections of the implant-bone interfaces were imaged with backscattered scanning electron microscopy and the percentage of available pore space that was filled with new bone was calculated. The mean extent of bone ingrowth was 6.6% for the control implants and 12.2% for the zoledronic acid-treated implants, an absolute difference of 5.6% (95% confidence interval, 1.2 to 10.1) and a relative difference of 85% which was statistically significant. Individual islands of new bone formation within the implant pores were similar in number in both groups but were 69% larger in the zoledronic acid-treated group. The bisphosphonate zoledronic acid should be further investigated for use in accelerating or enhancing the biological fixation of implants to bone.
Bobyn
J D
JD
Department of Surgery, McGill University, Montreal, Quebec, Canada. jdbobyn@hotmail.com
Hacking
S A
SA
Krygier
J J
JJ
Harvey
E J
EJ
Little
D G
DG
Tanzer
M
M
D000818:Animals; D016025:Bone Transplantation / Q000379:methods*; D004164:Diphosphonates / Q000494:pharmacology*; D004285:Dogs; D007093:Imidazoles / Q000494:pharmacology*; D008855:Microscopy, Electron, Scanning; D016348:Osseointegration / Q000187:drug effects*; D019736:Prostheses and Implants; D013635:Tantalum; D014457:Ulna / Q000502:physiology*; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D013635:Tantalum; D000077211:Zoledronic Acid